CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Stem Cell Sciences Plc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Stem Cell Sciences Plc.
7707 Gateway Blvd. Suite 140
Phone: +1 (510) 456-4000p:+1 510 456-4000 Newark, CA  94560  United States Ticker: STEM STEM
This company was Merged or Acquired on 4/1/2009.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Stem Cell Sciences (SCS) is an international research and development company focusing on the commercial application of stem cell biology technologies for drug discovery and regenerative medicine research. Stem Cell Sciences is focusing on building revenues through the sale of products, collaborative research and licensing deals with international biotechnology and pharmaceutical companies. The Company operations in the United States and Australia. The Company is a provider of cells and cell culture media to the burgeoning stem cell research market. SCS has multiple industry collaborations, including Millipore Corporation for the marketing and distribution of HEScGRO, its serum free media for the growth of human embryonic stem cells, and Merck & Co for the use of mouse neural stem cell technology for research applications. In April 2009, StemCells, Inc. completed the acquisition of substantially all of the operating assets and liabilities of the Company.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/200812/31/2007Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board David A.Dodd 57 1/1/2007 10/9/2006
Chief Executive Officer, Executive Director Alastair J.Riddell 58 11/21/2007 11/19/2007
Finance Director, Joint Company Secretary GiorgioReggiani 10/3/2008 2/15/2008
5 additional Officers and Directors records available in full report.

Business Names
Business Name
STEM
Stem Cell Sciences
Stem Cell Sciences PLC
Stem Cell Sciences Plc.
StemCellSciences UK Ltd.

General Information
Number of Employees: 34 (As of 12/31/2007)
Outstanding Shares: 33,516,149 (As of 4/22/2008)
Stock Exchange: SEA
Fax Number: +1 (510) 456-4001
Email Address: info@stemcellgb.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023